MedTrace Logo

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

NCT06439225 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2026-04-16

No results posted yet for this study

Summary

The usual approach for most patients who are not in a study is treatment with docetaxel.

This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach?

This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.

Conditions

Interventions

DRUG

Docetaxel

75mg/m2 q21 days

DRUG

Carboplatin

AUC5 q21 days

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Michael Kolinsky · Cross Cancer Institute, Edmonton, Alberta, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2029-09-30
Completion
2030-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06439225 on ClinicalTrials.gov